Metformin and metabolic diseases: a focus on hepatic aspects
- 12 February 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Frontiers of Medicine
- Vol. 9 (2), 173-186
- https://doi.org/10.1007/s11684-015-0384-0
Abstract
Metformin has been widely used as a first-line anti-diabetic medicine for the treatment of type 2 diabetes (T2D). As a drug that primarily targets the liver, metformin suppresses hepatic glucose production (HGP), serving as the main mechanism by which metformin improves hyperglycemia of T2D. Biochemically, metformin suppresses gluconeogenesis and stimulates glycolysis. Metformin also inhibits glycogenolysis, which is a pathway that critically contributes to elevated HGP. While generating beneficial effects on hyperglycemia, metformin also improves insulin resistance and corrects dyslipidemia in patients with T2D. These beneficial effects of metformin implicate a role for metformin in managing non-alcoholic fatty liver disease. As supported by the results from both human and animal studies, metformin improves hepatic steatosis and suppresses liver inflammation. Mechanistically, the beneficial effects of metformin on hepatic aspects are mediated through both adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. In addition, metformin is generally safe and may also benefit patients with other chronic liver diseases.This publication has 155 references indexed in Scilit:
- Molecular mechanism of action of metformin: old or new insights?Diabetologia, 2013
- Cellular and molecular mechanisms of metformin: an overviewClinical Science, 2011
- AMPK Phosphorylates and Inhibits SREBP Activity to Attenuate Hepatic Steatosis and Atherosclerosis in Diet-Induced Insulin-Resistant MiceCell Metabolism, 2011
- AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespanJournal of Molecular Medicine, 2011
- Metformin selectively attenuates mitochondrial H2O2 emission without affecting respiratory capacity in skeletal muscle of obese ratsFree Radical Biology & Medicine, 2010
- Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF ExpressionCell, 2010
- Immature myeloid cells induced by a high-fat diet contribute to liver inflammationHepatology, 2009
- Metformin and Insulin Suppress Hepatic Gluconeogenesis through Phosphorylation of CREB Binding ProteinCell, 2009
- Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient miceBiochemical Journal, 2008
- Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitisJournal of Hepatology, 2007